Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors

  • Authors:
    • Alessandro Villanucci
    • Ketty Tavella
    • Laura Vannini
    • Virginia Rossi
    • Stefania Nobili
    • Gianni Amunni
    • Teresita Mazzei
    • Enrico Mini
  • View Affiliations

  • Published online on: October 1, 2018     https://doi.org/10.3892/mco.2018.1729
  • Pages: 635-639
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The majority of patients with ovarian cancer will experience relapse and thus require second‑line therapy. While platinum-based therapies are the primary treatments for refractory disease other options are required, particularly for those with partially platinum‑sensitive disease as their response rates are lower. Agents that can resensitize relapsed ovarian cancers to platinum, including trabectedin, are therefore of increasing interest. Trabectedin is a multitarget agent that has a complex, novel mechanism of action and has exhibited promising results in platinum‑sensitive ovarian cancer when in combination with pegylated liposomal doxorubicin (PLD). The present study conducted retrospective analysis involving 11 cases (median age 60 years; range 45‑75 years) of recurrent ovarian tumors and partial platinum sensitivity undergoing treatment with trabectedin + PLD. The cohort consisted of 7 serous carcinomas, 1 endometrial carcinoma, 2 undifferentiated carcinomas, and 1 mucinous carcinoma. Of the 11 patients, 4 exhibited a complete response, 3 achieved stable disease, and 4 had progression of disease. Mean overall survival was 32.42 months and median progression‑free survival was 5.9 months. Trabectedin in combination with PLD was well tolerated in terms of gastrointestinal and hematological toxicity; Grade 3 cutaneous toxicity and grade 3 neutropenia were each observed in 18.2% of patients. There were no grade 4 events. Thus, the present study supports the use of trabectedin + PLD in patients with relapsed ovarian cancer and partial platinum sensitivity, with predictable and manageable toxicity.
View Figures
View References

Related Articles

Journal Cover

December-2018
Volume 9 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Villanucci A, Tavella K, Vannini L, Rossi V, Nobili S, Amunni G, Mazzei T and Mini E: Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors. Mol Clin Oncol 9: 635-639, 2018
APA
Villanucci, A., Tavella, K., Vannini, L., Rossi, V., Nobili, S., Amunni, G. ... Mini, E. (2018). Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors. Molecular and Clinical Oncology, 9, 635-639. https://doi.org/10.3892/mco.2018.1729
MLA
Villanucci, A., Tavella, K., Vannini, L., Rossi, V., Nobili, S., Amunni, G., Mazzei, T., Mini, E."Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors". Molecular and Clinical Oncology 9.6 (2018): 635-639.
Chicago
Villanucci, A., Tavella, K., Vannini, L., Rossi, V., Nobili, S., Amunni, G., Mazzei, T., Mini, E."Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors". Molecular and Clinical Oncology 9, no. 6 (2018): 635-639. https://doi.org/10.3892/mco.2018.1729